Sprint Precision Technologies
688605
Jiangsu Jingxue Insulation Technology
301010
Global Infotech
300465
Hydsoft Technology
301316
SGSG Science&Technology
300561
CN Stock MarketDetailed Quotes
002727 Yixintang Pharmaceutical
- 14.92
- +0.44+3.04%
Not Open Dec 12 15:00 CST
8.89BMarket Cap56.95P/E (TTM)
14.97High14.36Low223.13KlotVolume14.45Open14.48Pre Close329.34MTurnover5.47%Turnover Ratio16.18P/E (Static)596.01MShares24.1752wk High1.16P/B6.08BFloat Cap10.8452wk Low15.93Limit Up407.71MShs Float48.70Historical High13.03Limit Down4.21%Amplitude4.27Historical Low0.40Dividend TTM14.76Avg Price82.60KlotAsk2.68%Div YieldTTM100Lot Size131.44KlotBid
Yixintang Pharmaceutical Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 6.06%13.59B | 7.26%9.31B | 14.96%5.1B | -0.29%17.38B | 6.55%12.81B | 8.92%8.68B | 11.02%4.44B | 19.50%17.43B | 14.55%12.03B | 18.85%7.97B |
| Operating revenue | 6.06%13.59B | 7.26%9.31B | 14.96%5.1B | -0.29%17.38B | 6.55%12.81B | 8.92%8.68B | 11.02%4.44B | 19.50%17.43B | 14.55%12.03B | 18.85%7.97B |
| Other operating revenue | ---- | -10.97%260.96M | ---- | 63.86%503.73M | ---- | 84.92%293.12M | ---- | -1.54%307.42M | ---- | -1.40%158.52M |
| Total operating cost | 9.67%13.12B | 10.49%8.9B | 15.97%4.78B | 3.02%16.46B | 6.81%11.96B | 7.58%8.05B | 8.63%4.12B | 18.86%15.98B | 16.48%11.2B | 22.78%7.49B |
| Operating cost | 8.28%9.28B | 10.69%6.38B | 20.44%3.55B | 2.85%11.65B | 10.03%8.57B | 10.77%5.76B | 11.42%2.95B | 23.12%11.32B | 19.89%7.79B | 27.00%5.2B |
| Operating tax surcharges | 23.13%40.51M | -4.89%21.37M | -7.45%10.35M | 118.49%78.93M | 23.26%32.9M | 35.04%22.47M | 72.86%11.18M | -8.33%36.13M | -2.74%26.69M | -2.03%16.64M |
| Operating expense | 13.01%3.39B | 9.55%2.22B | 5.83%1.09B | 4.00%4.23B | -0.69%3B | 0.61%2.03B | 2.90%1.03B | 10.03%4.07B | 9.51%3.02B | 14.68%2.01B |
| Administration expense | 5.10%337.2M | 5.96%227.89M | -5.39%106.31M | -2.80%428.06M | 8.30%320.84M | 7.41%215.07M | -1.00%112.38M | 10.35%440.38M | 6.47%296.25M | 8.37%200.23M |
| Financial expense | 87.10%72.72M | 110.50%42.73M | 9.00%18.53M | -36.19%62.22M | -45.45%38.87M | -58.72%20.3M | -32.79%17M | -3.32%97.51M | 25.02%71.25M | 30.94%49.17M |
| -Interest expense (Financial expense) | 15.48%109.26M | 22.55%72.24M | -2.60%35.7M | -8.01%135.34M | -9.54%94.62M | -13.92%58.94M | 2.80%36.66M | 8.00%147.12M | 28.51%104.59M | 32.81%68.48M |
| -Interest Income (Financial expense) | 32.03%-40.05M | 22.36%-31.88M | 10.16%-18.29M | -45.26%-77.57M | -60.96%-58.93M | -92.78%-41.06M | -79.29%-20.35M | -36.06%-53.4M | -34.98%-36.61M | -36.15%-21.3M |
| Research and development | 4.42%7.99M | 24.05%5.58M | 70.83%2.83M | 16.70%10.2M | 98.60%7.65M | 166.53%4.49M | 72.47%1.66M | 62.23%8.74M | -0.38%3.85M | -55.63%1.69M |
| Credit Impairment Loss | 18.21%-5.63M | -5.29%-5.13M | -28.66%-9.21M | 49.20%-42.78M | 26.02%-6.88M | -35.65%-4.87M | 28.50%-7.16M | -1,729.09%-84.22M | -131.15%-9.3M | -41.80%-3.59M |
| Asset Impairment Loss | -10.50%-104.95M | -11.92%-73.12M | 14.20%-31.51M | 6.29%-164.94M | -3.62%-94.97M | -45.55%-65.33M | -138.01%-36.73M | -45.11%-176.01M | -25.66%-91.66M | 7.21%-44.89M |
| Other net revenue | -7.26%-66.41M | 6.23%-48.16M | 2.65%-33.32M | 36.67%-134.23M | 19.58%-61.92M | -114.11%-51.36M | -1,698.46%-34.22M | -173.58%-211.97M | -224.95%-76.99M | -51.58%-23.99M |
| Fair value change income | ---- | ---- | ---- | -46.02%-8.36M | ---- | ---- | ---- | 0.86%-5.72M | ---- | --355.83K |
| Invest income | 25.17%-5.72M | 30.97%-3.06M | 68.58%-637.17K | 18.98%8.92M | -249.03%-7.64M | -196.99%-4.44M | -376.29%-2.03M | -47.51%7.49M | -64.76%5.13M | -66.54%4.57M |
| -Including: Investment income associates | 19.21%-5.75M | 20.90%-3.09M | 68.92%-637.17K | -675.34%-7.34M | -109.32%-7.12M | -119.98%-3.91M | -84.86%-2.05M | 72.59%-946.55K | -93.13%-3.4M | -79.32%-1.78M |
| Asset deal income | -830.74%-7.41M | 0.84%-9.35M | -36.54%-11.42M | 108.07%1.12M | -175.36%-796.21K | -662.00%-9.43M | -197.19%-8.36M | -3.10%-13.83M | --1.06M | --1.68M |
| Other revenue | 18.44%57.3M | 29.93%42.51M | -2.97%19.46M | 19.07%71.82M | 172.08%48.38M | 82.93%32.72M | 22.92%20.06M | 13.09%60.32M | -54.07%17.78M | -16.48%17.89M |
| Operating profit | -48.99%401.17M | -37.20%358.4M | 2.19%285.21M | -36.72%786.44M | 5.38%786.5M | 25.44%570.71M | 37.86%279.09M | 16.37%1.24B | -12.98%746.37M | -22.69%454.97M |
| Add:Non operating Income | 78.44%2.95M | 27.04%1.45M | 66.96%1.08M | -65.85%2.95M | -94.46%1.65M | -93.91%1.14M | -91.20%649.09K | -76.91%8.63M | 46.76%29.83M | 25.99%18.73M |
| Less:Non operating expense | 567.52%36.15M | 586.10%17.6M | -50.93%663.66K | 430.46%86.83M | 7.60%5.42M | -29.77%2.57M | 170.78%1.35M | 86.10%16.37M | -36.44%5.03M | -44.04%3.65M |
| Total profit | -52.99%367.97M | -39.88%342.25M | 2.60%285.63M | -43.11%702.56M | 1.50%782.73M | 21.11%569.28M | 33.00%278.38M | 12.63%1.23B | -11.38%771.17M | -21.24%470.06M |
| Less:Income tax cost | -32.59%61.3M | -20.14%48.97M | 11.58%39.32M | -35.97%142.15M | -5.65%90.93M | 12.05%61.33M | 2.92%35.24M | 23.80%222M | -10.71%96.38M | -26.37%54.73M |
| Net profit | -55.67%306.67M | -42.26%293.27M | 1.30%246.31M | -44.68%560.41M | 2.52%691.8M | 22.30%507.95M | 38.88%243.15M | 10.44%1.01B | -11.47%674.79M | -20.51%415.32M |
| Net profit from continuing operation | -55.67%306.67M | -42.26%293.27M | 1.30%246.31M | -44.68%560.41M | 2.52%691.8M | 22.30%507.95M | 38.88%243.15M | 10.44%1.01B | -11.47%674.79M | -20.51%415.32M |
| Less:Minority Profit | 140.87%14.17M | 236.61%11.37M | 19.26%4.39M | 267.90%10.97M | 328.53%5.88M | 215.65%3.38M | 185.54%3.68M | 168.13%2.98M | -52.26%-2.57M | -116.28%-2.92M |
| Net profit of parent company owners | -57.36%292.5M | -44.13%281.9M | 1.03%241.92M | -45.60%549.44M | 1.26%685.92M | 20.64%504.58M | 33.49%239.46M | 9.59%1.01B | -11.33%677.37M | -20.16%418.24M |
| Earning per share | ||||||||||
| Basic earning per share | -57.47%0.4908 | -44.28%0.473 | 0.69%0.4059 | -45.91%0.9207 | 1.01%1.1539 | 20.24%0.8489 | 32.64%0.4031 | 9.01%1.7022 | -11.74%1.1424 | -20.46%0.706 |
| Diluted earning per share | -57.43%0.4908 | -44.20%0.473 | 1.05%0.4059 | -45.74%0.9206 | 1.13%1.153 | 20.34%0.8477 | 32.36%0.4017 | 9.05%1.6968 | -11.62%1.1401 | -20.36%0.7044 |
| Other composite income | -289.75%-6.19M | 104.25%83.04K | 104.52%104.83K | 97.65%-62.53K | 25.31%3.26M | -1,543.16%-1.95M | -2,456.73%-2.32M | |||
| Other composite income of parent company owners | ---- | ---- | ---- | -289.75%-6.19M | 104.25%83.04K | 104.52%104.83K | 97.65%-62.53K | 25.31%3.26M | -1,543.16%-1.95M | -2,456.73%-2.32M |
| Total composite income | -55.68%306.67M | -42.28%293.27M | 1.33%246.31M | -45.46%554.22M | 2.83%691.89M | 23.01%508.06M | 40.99%243.08M | 10.48%1.02B | -11.74%672.84M | -20.97%413.01M |
| Total composite income of parent company owners | -57.36%292.5M | -44.14%281.9M | 1.05%241.92M | -46.39%543.25M | 1.57%686M | 21.34%504.68M | 35.47%239.4M | 9.64%1.01B | -11.60%675.41M | -20.62%415.93M |
| Total composite income of minority owners | 140.87%14.17M | 236.61%11.37M | 19.26%4.39M | 267.90%10.97M | 328.53%5.88M | 215.65%3.38M | 185.54%3.68M | 168.13%2.98M | -52.26%-2.57M | -116.28%-2.92M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | China Audit Zhonghuan Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | China Audit Zhonghuan Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
